Review Article
Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females
Table 4
Cross protection offered by Cervarix [66].
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Infection definitions: 6-month definition required the detection of the same HPV type in two consecutive cervical samples, with no negative sample in between, over a minimum of 5 months. CIN 2+ means cervical intraepithelial neoplasia grades 2 and 3 and adenocarcinoma insitu. Lesions may be coinfected with HPV 16/18. TVC means total vaccinated cohort: women with at least one injection, seropositive or negative, PCR positive or negative for one or more HPV types at baseline, regardless of Pap result; case counting starting first day after first injection. TVC-N means TVC naive: women who received ≥1 vaccine dose with normal cytology, seronegative for HPV-16/18 and DNA-negative for 14 oncogenic HPV types at baseline (16, 18, 31. 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68); case counting starting first day after first injection. Subjects were followed for an average 44.3 months after first injection. |